All In Biotech

Drug Trial Radar · NCT05843578

STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

103

Actual

Start

Aug 1, 2023

Primary completion

Jun 20, 2026

Study completion Jun 20, 2026

Sponsor

Lead sponsor
Agomab Spain S.L.U.Industry
Sponsor type
Industry
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Many patients with Crohn's disease develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the safety, pharmacokinetics, and pharmacodynamics of AGMB-129 (Ontunisertib) in patients with Crohn's disease and symptomatic strictures, and whether it can have a beneficial effect on intestinal strictures. The participants will be in the Part A for a duration of up to 19 weeks including a 5 week screening period, a 12-week double-blind, placebo-controlled treatment period, and 2 week safety follow up period. Participants who continue to Part B can receive treatment for up to an additional 48 weeks, with a safety follow-up visit 2 weeks after the last dose of treatment.

Conditions

  • Fibrostenotic Crohn's Disease

Interventions

  • AGMB-129Drug

    Oral capsule

  • PlaceboDrug

    Matching oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (Part A and B)Time frame: From Screening to Week 48
  2. Number of participants with abnormal clinical laboratory values (Part A and B)Time frame: From Screening to Week 48
  3. Number of participants with abnormal ECG parameters (Part A and B)Time frame: From Screening to Week 48
  4. Number of participants with abnormal vital signs (Part A and B)Time frame: From Screening to Week 48
  5. Number of participants with abnormal physical exams (Part A and B)Time frame: From Screening to Week 48
  6. Number of participants with abnormal 2D-echocardiography (Part A and B)Time frame: From Screening to Week 48

Locations

52 sites in 8 countries. Site status is shown where the registry gives one.

  • Medical Research Center of Connecticut, LLC

    Hamden, Connecticut

  • University of Miami

    Miami, Florida

  • Digestive and Liver Center of Florida

    Orlando, Florida

  • Gastroenterology Health Partners

    New Albany, Indiana

  • Gastroenterology Health Partners

    Louisville, Kentucky

  • Louisiana Research Center

    Shreveport, Louisiana

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Cleveland Clinic

    Cleveland, Ohio

  • Gastro One

    Cordova, Tennessee

  • Medical University of Graz

    Graz, Austria

  • Gemeinnutzige Salzburger Landeskliniken Betriebsgesellschaft mbH (Landeskrankenhaus Salzburg/Regional Hospital Salzburg)

    Salzburg, Austria

  • Medical University Of Vienna (AKH Wien)

    Vienna, Austria

  • Hospital Landstrasse, Department of Internal Medicine IV

    Vienna, Austria

  • University of Calgary

    Calgary, Canada

  • Gastroenterology and Internal Medicine Research Institute (GIRI)

    Edmonton, Canada

  • South Edmonton Gastroenterology Research Clinic

    Edmonton, Canada

  • Nova Scotia Health Authority

    Halifax, Canada

  • TIDHI Innovation Inc.

    North York, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Canada

  • (G.I.R.I) GI Research Institute

    Vancouver, Canada

  • Aarhus University Hospital, Department of Hepatology and Gastroenterology

    Aarhus, Denmark

  • Bispebjerg Hospital

    Copenhagen, Denmark

  • Rigshospitalet - University Hospital Copenhagen

    Copenhagen, Denmark

  • Herlev Hospital (University of Copenhagen)

    Herlev, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Charite Universitatsmedizin Berlin KöR Campus Benjamin Franklin Medizinische

    Berlin, Germany

  • Servicegesellschaft Krankenhaus Waldfriede mbH Krankenhaus Waldfriede e.V Akademisches Lehrkrankenhaus der Charite

    Berlin, Germany

  • BSF Studiengesellschaft UG (Unternehmergesellschaft, haftungsbeschränkt)

    Halle, Germany

  • Universitatsklinikum Ulm AöR (University of Ulm)

    Ulm, Germany

  • University Polyclinic Hospital "G. Martino"

    Messina, Italy

  • Humanitas Research Hospital IRCCS Istituto Clinico Humanitas

    Milan, Italy

  • Hospital San Raffaele

    Milan, Italy

  • Azienda Ospedaliero Universitaria di Modena - Struttura Complessa di Gastroenterologia

    Modena, Italy

  • Sacred Heart Don Calabria

    Negrar, Italy

  • Azienda Ospedaliera San Camillo Forlanini

    Rome, Italy

  • University Polyclinic Foundation "Agostino Gemelli"

    Rome, Italy

  • Specialist Gastrology Centre GASTROMED

    Bialystok, Poland

  • Vita Longa Sp. z.o.o.

    Katowice, Poland

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.